Skip to main content
TipRanks
Go Ultimate75% OFF

MannKind (MNKD) Q3 2026 Earnings Report

2,104 Followers

MNKD Q3 2026 EPS Results

Actual EPS
-$0.07
Consensus EPS
-$0.07
Beat/Miss
Missed by -$0.00
One Year Ago EPS
$0.03

MNKD Q3 2026 Revenue Results

Actual Revenue
$101.87M
Expected Revenue
$107.03M
Beat/Miss
Missed by -$5.16M
YoY Revenue Growth
+24.04%

Earnings Announcement Details

Quarter
Q3 2026
Date
11/05/2026
Time
After Close
Conference Call
Thursday, November 5, 2026
MNKD Upcoming Earnings

MannKind's next earnings date is estimated for February 25, 2027, based on past reporting schedules.

Q3 2026 Earnings Call Audio

MNKD Q3 2026 Earnings Call
0:00 / 0:00

Q3 2026 Earnings Slide Deck

Q3 2026 Earnings Call Summary

Q3 2026
Earnings Call Date:Nov 05, 2026|% Change Since:8.24%|
Earnings Call Sentiment|Positive

The call was strongly optimistic, with management highlighting 24% quarterly revenue growth, 27% year-to-date growth, rapid Furoscix ReadyFlow adoption, strong pediatric Afrezza uptake, increasing royalties, and an expected return to profitability in Q4 and for full-year 2027. The company also outlined a broad product and pipeline expansion plan. The main negative points were current GAAP losses, adult Afrezza underperformance, temporary Furoscix revenue disruption during the ReadyFlow transition, reimbursement challenges, and lower quarterly collaboration and services revenue. Highlights significantly outweighed the lowlights.

Company Guidance

MannKind expects record revenue in Q4 will drive us to profitability as we close out the year and expects to return to profitability in the fourth quarter on both a GAAP and a non-GAAP basis; Furoscix Q4 sales should match the entire first half of 2027, are expected to be “roughly equal, plus or minus a little bit to the first half,” putting them “in the $38 million range,” and should be more than the entire first half of 2026, while collaboration and services revenue for the year is expected to be consistent with the 2025 total. The company expects to be profitable in 2027 on an annual basis, “not necessarily in Q1,” with stable investment on the expense side, anticipates $15 million in milestones from ralinepag DPI in 2027, estimates its United Therapeutics license agreement will provide more than $1 billion in revenue from 2027 through 2030, expects the INFLO-2 data readout in the first half of 2028 from about 150 patients across 85 sites, expects 90% plus scripts in Q4 to be for the auto-injector, expects approval of the Afrezza 2-unit cartridge and launch of INHALE IQ next year, and hopes to introduce 16 and 20-unit Afrezza cartridges.

  • Strong Revenue Growth and Expected Return to ProfitabilityThird-quarter total revenue was $101.9 million, up 24% from $82.1 million in the third quarter of 2025. Year-to-date revenue was $301.4 million, up 27% from $237.0 million. Management expects record fourth-quarter revenue to drive profitability in Q4 on both a GAAP and non-GAAP basis and expects to be profitable in 2027 on an annual basis.
  • Long-Term Transformation and Revenue DiversificationMannKind said revenue has grown at a compound annual rate of more than 40% over five years, from roughly $75 million to an expected 2026 scale close to 6x larger. The company now has 4 FDA-approved products and described itself as a diversified growth company rather than a single-product business.
  • Commercial Product Revenue More Than Doubled Year to DateYear-to-date commercial product revenue from Afrezza and Furoscix increased from $52 million to $112 million, up 116%. Separately, reported year-to-date commercial product revenue was $120.9 million, up 90%, with Furoscix contributing $60.1 million.
  • Furoscix ReadyFlow Adoption Exceeded ExpectationsFuroscix ReadyFlow was approved, and by late October roughly 75% of Furoscix shipments had moved to ReadyFlow, exceeding internal expectations by several quarters. In six weeks, nearly 75% of prescriptions had converted, more than 1,600 prescribers had written their first prescription, and prescriptions grew about 56% in the six weeks after launch versus the prior six weeks.
  • Furoscix Growth Broadening Across Patients and PrescribersManagement said most ReadyFlow patients were new to brand and that growth was coming from new-to-brand patients and new prescribers, including significant increases from nephrology and cardiology. The company expects Furoscix fourth-quarter sales to be roughly equal to the first half of 2026, or approximately $38 million, and said fourth-quarter revenue should exceed revenue from the entire first half of 2026.
  • Furoscix Margin Benefit from ReadyFlow ConversionReadyFlow has a meaningfully lower cost of goods than the On-body Infuser. Management stated that the faster conversion to ReadyFlow allows the associated margin improvement to flow through to the bottom line.
  • Furoscix Market Opportunity and Commercial Expansion PlansIndependent research conducted with L.E.K. identified roughly 1 million patients annually at each stage of the fluid-overload journey, with physicians indicating they would prescribe Furoscix to a significant share at each stage. The company plans to generate additional evidence and physician guidance, expand awareness and reach in nephrology and IDNs, improve hub and distribution processes, and increase Furoscix sales-force share of voice and footprint in 2027.
  • Afrezza Pediatric Launch Delivered Strong Early AdoptionThe Afrezza pediatric launch exceeded internal forecasts for institutional and healthcare-provider adoption as well as total prescriptions. Average monthly new-to-brand prescriptions increased nearly 80% in Q3 versus Q2, and pediatric patients represented about 1 in 4 Afrezza prescriptions. More than 2,000 pediatric patients had been treated, approximately 600 pediatric prescribers had prescribed Afrezza, and all 60 priority pediatric institutions had prescribed it.
  • Afrezza Returned to Growth in the Third QuarterAfrezza generated $19.3 million in third-quarter net revenue, up about 5% year over year, while total prescriptions grew roughly 17% sequentially. Management said the pediatric launch returned the brand to growth, with Q3 new patient starts coming close to matching the total from the first half of the year.
  • Improving Pediatric Reimbursement and Institutional AdoptionMore than half of pediatric prescriptions were already being reimbursed by insurance. Management said approval rates improved from May and June to October, reimbursement-support resources were expanded, and discussions with payers could lead to coverage criteria being reduced to a single failed injectable step in some cases.
  • Tyvaso DPI Royalty Growth and Partner DemandUnited Therapeutics reported third-quarter Tyvaso DPI sales of $379 million, returning to growth. MannKind's third-quarter royalty revenue increased to $37.5 million, up 12% year over year and 16% versus Q2, driven by Tyvaso DPI growth. Management cited stronger underlying demand, more consistent commercial execution, increased adoption of higher-dose cartridges, and improving referrals beginning in September.
  • Durable Collaboration Revenue BaseYear-to-date royalty revenue grew 8% to $102.6 million, while collaboration and services revenue was $77.9 million, in line with the prior-year period. Management expects full-year 2026 collaboration and services revenue to be consistent with the 2025 total and estimates that the United Therapeutics license agreement will provide more than $1 billion in revenue from 2027 through 2030.
  • Positive Nintedanib DPI Phase Ib ResultsMannKind reported positive Phase Ib results for nintedanib DPI in the INFLO-1 study, demonstrating safety and tolerability, particularly regarding cough in patients with IPF.
  • Nintedanib DPI Phase II Trial ProgressingThe global INFLO-2 Phase II study is a 12-week placebo-controlled trial of two doses in patients with IPF, followed by a six-month open-label extension. The protocol was streamlined to about 150 patients, several countries have approved the updated protocol, and MannKind is activating 85 sites globally. The company expects a data readout in the first half of 2028 and said the study will include early reads on lung spirometry parameters such as FEV1 and FVC.
  • Three Potential IPF Development PathsManagement described three potential IPF paths based on its Technosphere platform: Tyvaso DPI through the United Therapeutics license, wholly owned nintedanib DPI, and partnered ralinepag DPI. Ralinepag DPI is progressing toward an IND, carries a 10% royalty similar to Tyvaso, and is expected to generate $15 million in milestones for MannKind in 2027.
  • Pipeline and Product Expansion Road MapFor 2027, MannKind expects approval of the Afrezza 2-unit cartridge and plans to launch INHALE IQ, a connected Bluetooth device that will bring CGM integration for Afrezza users. The company is also advancing a Furoscix 40-milligram auto-injector pen and higher-concentration Afrezza products intended to enable 16- and 20-unit cartridges and reduce powder per inhalation.
  • Financing Completed for CVR PaymentMannKind closed a $50 million private placement led by Frazier Life Sciences, which funded the $45 million CVR payment triggered by ReadyFlow approval. Management characterized the financing as a strong endorsement of its strategy from a long-term investor.

MNKD Earnings History

MNKD earnings history
Report DateFiscal QuarterForecast / EPSLast Year's EPSEPS YoY ChangePress Release
Feb 25, 20272026 (Q4)0.01--0.05――
Nov 05, 20262026 (Q3)-0.07-0.070.03-333.33% (-0.10)
Aug 05, 20262026 (Q2)-0.01-0.060―
May 06, 20262026 (Q1)0.00-0.050.04-225.00% (-0.09)
Feb 26, 20262025 (Q4)0.02-0.050.03-266.67% (-0.08)
Nov 05, 20252025 (Q3)0.020.030.04-25.00% (-0.01)
Aug 06, 20252025 (Q2)0.050.00-0.01100.00% (+0.01)
May 08, 20252025 (Q1)0.040.040.040.00% (+0.00)
Feb 26, 20252024 (Q4)0.040.030―
Nov 07, 20242024 (Q3)0.030.040.01300.00% (+0.03)

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat Missed